Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Dalbavancin Critical Pathway for ABSSSI
NCT03233438Phase 4Completed
- Sponsor
- Allergan
- Start
- Jul 2017
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Allergan. Primary endpoint: Number of Infection-related Total Admitted Hospital Days at 44 Days. Started Jul 2017; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03233438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233438.